Nuzenio

Is Roivant Sciences

Is Roivant Sciences news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 24 latest news signals 14 publisher sources 100/100 entity strength

Latest news

Roivant Sciences Ltd. (ROIV) stock price, news, quote and history - Yahoo Finance SingaporeYahoo Finance Singapore · Sun, 09 Aug 2026 21:35:26 GMT Is Roivant Sciences’ (ROIV) Cost Discipline Offsetting Slower Revenue Enough to Refresh Its Story? - Yahoo FinanceYahoo Finance · Sun, 09 Aug 2026 20:11:13 GMT Is Roivant Sciences (ROIV) Overvalued On First Quarter Results? - Yahoo Finance UKYahoo Finance UK · Sun, 09 Aug 2026 15:09:25 GMT Roivant: $950 Million Moderna Payment Arrives As Another $1.3 Billion Remains Contingent On Patent Appeal - Pulse 2.0Pulse 2.0 · Sun, 09 Aug 2026 11:56:09 GMT Roivant Sciences (ROIV) Is Up 7.2% After Narrower Net Loss Despite Lower Quarterly Revenue - simplywall.stsimplywall.st · Sun, 09 Aug 2026 11:45:55 GMT Roivant Sciences shifts to commercial biopharma with $4.7B cash, eyeing FDA approval for brepocitinib by 2026 - pluang.compluang.com · Sat, 08 Aug 2026 12:25:35 GMT Roivant Sciences (ROIV) Stock Rally Leans On Cash As Losses Persist - simplywall.stsimplywall.st · Sat, 08 Aug 2026 06:38:12 GMT Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and MailThe Globe and Mail · Fri, 07 Aug 2026 20:04:25 GMT

Timeline

Sun, 09 Aug 2026 21:35:26 GMTRoivant Sciences Ltd. (ROIV) stock price, news, quote and history - Yahoo Finance Singapore

Sun, 09 Aug 2026 20:11:13 GMTIs Roivant Sciences’ (ROIV) Cost Discipline Offsetting Slower Revenue Enough to Refresh Its Story? - Yahoo Finance

Sun, 09 Aug 2026 15:09:25 GMTIs Roivant Sciences (ROIV) Overvalued On First Quarter Results? - Yahoo Finance UK

Sun, 09 Aug 2026 11:56:09 GMTRoivant: $950 Million Moderna Payment Arrives As Another $1.3 Billion Remains Contingent On Patent Appeal - Pulse 2.0

Sun, 09 Aug 2026 11:45:55 GMTRoivant Sciences (ROIV) Is Up 7.2% After Narrower Net Loss Despite Lower Quarterly Revenue - simplywall.st

Sat, 08 Aug 2026 12:25:35 GMTRoivant Sciences shifts to commercial biopharma with $4.7B cash, eyeing FDA approval for brepocitinib by 2026 - pluang.com

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

ROIV20 live mentions Roivant Sciences13 live mentions Roivant Sciences Ltd11 live mentions Yahoo Finance Yahoo6 live mentions Finance6 live mentions Earnings Call Highlights6 live mentions Yahoo Finance Roivant4 live mentions Ltd4 live mentions June4 live mentions EPS4 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Is Roivant Sciences.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

14 distinct publisher/source names are currently connected to this entity page.